aTyr Pharma Statistics
Total Valuation
aTyr Pharma has a market cap or net worth of $50.90 million. The enterprise value is $4.78 million.
| Market Cap | 50.90M |
| Enterprise Value | 4.78M |
Important Dates
The last earnings date was Friday, August 7, 2026, after market close.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
aTyr Pharma has 98.09 million shares outstanding. The number of shares has increased by 16.75% in one year.
| Current Share Class | 98.09M |
| Shares Outstanding | 98.09M |
| Shares Change (YoY) | +16.75% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 2.59% |
| Owned by Institutions (%) | 39.69% |
| Float | 95.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 270.36 |
| Forward PS | n/a |
| PB Ratio | 1.12 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 27.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.12, with a Debt / Equity ratio of 0.23.
| Current Ratio | 5.12 |
| Quick Ratio | 5.08 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.68% and return on invested capital (ROIC) is -54.22%.
| Return on Equity (ROE) | -98.68% |
| Return on Assets (ROA) | -46.58% |
| Return on Invested Capital (ROIC) | -54.22% |
| Return on Capital Employed (ROCE) | -109.29% |
| Weighted Average Cost of Capital (WACC) | 5.82% |
| Revenue Per Employee | $3,167 |
| Profits Per Employee | -$1.01M |
| Employee Count | 60 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.41% in the last 52 weeks. The beta is 0.52, so aTyr Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | -89.41% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 49.06 |
| Average Volume (20 Days) | 715,119 |
Short Selling Information
The latest short interest is 9.73 million, so 9.92% of the outstanding shares have been sold short.
| Short Interest | 9.73M |
| Short Previous Month | 8.28M |
| Short % of Shares Out | 9.92% |
| Short % of Float | 10.18% |
| Short Ratio (days to cover) | 7.07 |
Income Statement
In the last 12 months, aTyr Pharma had revenue of $190,000 and -$60.81 million in losses. Loss per share was -$0.62.
| Revenue | 190,000 |
| Gross Profit | -59.95M |
| Operating Income | -63.86M |
| Pretax Income | -60.81M |
| Net Income | -60.81M |
| EBITDA | -63.20M |
| EBIT | -63.86M |
| Loss Per Share | -$0.62 |
Balance Sheet
The company has $57.42 million in cash and $11.30 million in debt, with a net cash position of $46.12 million or $0.47 per share.
| Cash & Cash Equivalents | 57.42M |
| Total Debt | 11.30M |
| Net Cash | 46.12M |
| Net Cash Per Share | $0.47 |
| Equity (Book Value) | 48.59M |
| Book Value Per Share | 0.50 |
| Working Capital | 46.97M |
Cash Flow
In the last 12 months, operating cash flow was -$54.54 million and capital expenditures -$279,000, giving a free cash flow of -$54.82 million.
| Operating Cash Flow | -54.54M |
| Capital Expenditures | -279,000 |
| Depreciation & Amortization | 661,000 |
| Net Borrowing | -562,000 |
| Free Cash Flow | -54.82M |
| FCF Per Share | -$0.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | -33,609.47% |
| Pretax Margin | -32,006.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
aTyr Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.75% |
| Shareholder Yield | -16.75% |
| Earnings Yield | -118.37% |
| FCF Yield | -106.72% |
Analyst Forecast
The average price target for aTyr Pharma is $2.86, which is 451.17% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.86 |
| Price Target Difference | 451.17% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2019. It was a reverse split with a ratio of 1:14.
| Last Split Date | Jul 1, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:14 |
Scores
aTyr Pharma has an Altman Z-Score of -10.13 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.13 |
| Piotroski F-Score | 1 |